145 related articles for article (PubMed ID: 31600808)
1. Effectiveness and Safety of Primary Thromboprophylaxis in Children with Cancer: A Systematic Review of the Literature and Network Meta-Analysis.
Pelland-Marcotte MC; Tole S; Pechlivanoglou P; Brandão LR
Thromb Haemost; 2019 Dec; 119(12):2034-2042. PubMed ID: 31600808
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for people with cancer and central venous catheters.
Akl EA; Ramly EP; Kahale LA; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2014 Oct; (10):CD006468. PubMed ID: 25318061
[TBL] [Abstract][Full Text] [Related]
3. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form.
Hu Z; Persaud Y; Ahuja S
Crit Rev Oncol Hematol; 2024 May; 197():104347. PubMed ID: 38583546
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
Akl EA; Kahale L; Sperati F; Neumann I; Labedi N; Terrenato I; Barba M; Sempos EV; Muti P; Cook D; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD009447. PubMed ID: 24966161
[TBL] [Abstract][Full Text] [Related]
8. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
Greiner J; Schrappe M; Claviez A; Zimmermann M; Niemeyer C; Kolb R; Eberl W; Berthold F; Bergsträsser E; Gnekow A; Lassay E; Vorwerk P; Lauten M; Sauerbrey A; Rischewski J; Beilken A; Henze G; Korte W; Möricke A;
Haematologica; 2019 Apr; 104(4):756-765. PubMed ID: 30262570
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies.
Bidlingmaier C; Kenet G; Kurnik K; Mathew P; Manner D; Mitchell L; Krümpel A; Nowak-Göttl U
Semin Thromb Hemost; 2011 Oct; 37(7):814-25. PubMed ID: 22187405
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Labedi N; Barba M; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Jun; (6):CD006650. PubMed ID: 21678361
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
Akl EA; Labedi N; Terrenato I; Barba M; Sperati F; Sempos EV; Muti P; Cook D; Schünemann H
Cochrane Database Syst Rev; 2011 Nov; (11):CD009447. PubMed ID: 22071865
[TBL] [Abstract][Full Text] [Related]
17. Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease.
Payne RM; Burns KM; Glatz AC; Male C; Donti A; Brandão LR; Balling G; VanderPluym CJ; Bu'Lock F; Kochilas LK; Stiller B; Cnota JF; Rahkonen O; Khan A; Adorisio R; Stoica S; May L; Burns JC; Saraiva JFK; McHugh KE; Kim JS; Rubio A; Chía-Vazquez NG; Meador MR; Dyme JL; Reedy AM; Ajavon-Hartmann T; Jarugula P; Carlson-Taneja LE; Mills D; Wheaton O; Monagle P
J Am Coll Cardiol; 2023 Dec; 82(24):2296-2309. PubMed ID: 38057072
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis.
Akl EA; Terrenato I; Barba M; Sperati F; Sempos EV; Muti P; Cook DJ; Schünemann HJ
Arch Intern Med; 2008 Jun; 168(12):1261-9. PubMed ID: 18574082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
